Norepinephrine-Dopamine Reuptake Inhibitor (NDRI)

A Norepinephrine-Dopamine Reuptake Inhibitor (NDRI) is a reuptake inhibitor for norepinephrine and dopamine.

• Context:
  • It can (typically) act by blocking the action of the norepinephrine transporter (NET) and the dopamine transporter (DAT), respectively. This in turn leads to increased extracellular concentrations of both norepinephrine and dopamine and, therefore, an increase in adrenergic and dopaminergic neurotransmission.
  • It can (typically) be a CNS Stimulant.
  • …
• Example(s):
  • Ritalin.
  • …
• Counter-Example(s):
  • a Selective Serotonin Reuptake Inhibitor (SSRI).
  • Methamphetamine.
  • a CNS Depressant.
• See: Norepinephrine–Dopamine Releasing Agent, Drug, Clinical Depression, Attention Deficit Hyperactivity Disorder, Narcolepsy, Management of Parkinson's Disease#Medication, Reuptake Inhibitor, Neurotransmitter, Norepinephrine, Dopamine, Norepinephrine Transporter, Dopamine Transporter.

---

---

References

2022

• (Wikipedia, 2022) ⇒ https://en.wikipedia.org/wiki/Norepinephrine–dopamine_reuptake_inhibitor Retrieved:2022-11-22.
  • A norepinephrine–dopamine reuptake inhibitor (NDRI) is a drug used for the treatment of clinical depression, attention deficit hyperactivity disorder (ADHD), narcolepsy, and the management of Parkinson's disease. The drug acts as a reuptake inhibitor for the neurotransmitters norepinephrine and dopamine by blocking the action of the norepinephrine transporter (NET) and the dopamine transporter (DAT), respectively. This in turn leads to increased extracellular concentrations of both norepinephrine and dopamine and, therefore, an increase in adrenergic and dopaminergic neurotransmission.

    A closely related type of drug is a norepinephrine–dopamine releasing agent (NDRA).

---